163 related articles for article (PubMed ID: 38266271)
1. Mycophenolate mofetil inhibits Merkel cell carcinoma growth.
Garman KA; Thoreson N; Strong J; Hallaert P; Gelb T; Shen M; Hall MD; Brownell I
Br J Dermatol; 2024 Mar; 190(4):593-595. PubMed ID: 38266271
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration.
Waller JR; Brook NR; Bicknell GR; Murphy GJ; Nicholson ML
Transplant Proc; 2005; 37(1):164-6. PubMed ID: 15808582
[TBL] [Abstract][Full Text] [Related]
3. Donor treatment with mycophenolate mofetil: protection against ischemia-reperfusion injury in the rat.
Valentin JF; Bruijn JA; Paul LC
Transplantation; 2000 Feb; 69(3):344-50. PubMed ID: 10706040
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil for maintenance of remission in steroid-dependent autoimmune pancreatitis.
Sodikoff JB; Keilin SA; Cai Q; Bharmal SJ; Lewis MM; Raju GS; Willingham FF
World J Gastroenterol; 2012 May; 18(18):2287-90. PubMed ID: 22611324
[TBL] [Abstract][Full Text] [Related]
5. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
Czaja AJ; Carpenter HA
J Clin Gastroenterol; 2005 Oct; 39(9):819-25. PubMed ID: 16145346
[TBL] [Abstract][Full Text] [Related]
6. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
Simmons WD; Rayhill SC; Sollinger HW
Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil: a unique immunosuppressive agent.
Hood KA; Zarembski DG
Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
[TBL] [Abstract][Full Text] [Related]
8. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.
Kirklin JK; Bourge RC; Naftel DC; Morrow WR; Deierhoi MH; Kauffman RS; White-Williams C; Nomberg RI; Holman WL; Smith DC
J Heart Lung Transplant; 1994; 13(3):444-50. PubMed ID: 8061021
[TBL] [Abstract][Full Text] [Related]
9. Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus.
Subedi A; Magder LS; Petri M
Rheumatol Int; 2015 Oct; 35(10):1687-92. PubMed ID: 25836768
[TBL] [Abstract][Full Text] [Related]
10. Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients.
Vrisekoop N; Sankatsing SU; Jansen CA; Roos MT; Otto SA; Schuitemaker H; Lange JM; Prins JM; Miedema F
AIDS Res Hum Retroviruses; 2005 Dec; 21(12):991-6. PubMed ID: 16379601
[TBL] [Abstract][Full Text] [Related]
11. Topical mycophenolate mofetil in the treatment of vitiligo: a pilot study.
Handjani F; Aghaei S; Moezzi I; Saki N
Dermatol Pract Concept; 2017 Apr; 7(2):31-33. PubMed ID: 28515990
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
[TBL] [Abstract][Full Text] [Related]
13. The use of mycophenolate mofetil in liver transplant recipients.
Detry O; de Roover A; Delwaide J; Meurisse M; Honoré P
Expert Opin Pharmacother; 2003 Nov; 4(11):1949-57. PubMed ID: 14596648
[TBL] [Abstract][Full Text] [Related]
14. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
15. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolaños-Meade J; Reshef R; Fraser R; Fei M; Abhyankar S; Al-Kadhimi Z; Alousi AM; Antin JH; Arai S; Bickett K; Chen YB; Damon LE; Efebera YA; Geller NL; Giralt SA; Hari P; Holtan SG; Horowitz MM; Jacobsohn DA; Jones RJ; Liesveld JL; Logan BR; MacMillan ML; Mielcarek M; Noel P; Pidala J; Porter DL; Pusic I; Sobecks R; Solomon SR; Weisdorf DJ; Wu J; Pasquini MC; Koreth J
Lancet Haematol; 2019 Mar; 6(3):e132-e143. PubMed ID: 30824040
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
17. The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance--no beneficial effect.
Ben-Ari Z; Zemel R; Tur-Kaspa R
Transplantation; 2001 Jan; 71(1):154-6. PubMed ID: 11211184
[TBL] [Abstract][Full Text] [Related]
18. Individualization of mycophenolate mofetil dose in renal transplant recipients.
van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil in primary glomerulopathies.
Sepe V; Libetta C; Giuliano MG; Adamo G; Dal Canton A
Kidney Int; 2008 Jan; 73(2):154-62. PubMed ID: 17989649
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Broen JCA; van Laar JM
Nat Rev Rheumatol; 2020 Mar; 16(3):167-178. PubMed ID: 32055040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
